IDEAYA Biosciences, Inc. (IDYA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	36.5M	218.7M	7.0M	23.4M	50.9M
Cost of Revenue	147.9M	314.7M	3.8M	4.0M	2.1M
Gross Profit	(111.3M)	(96.0M)	3.2M	19.4M	48.8M
Operating Expenses
R&D Expense	412.6M	314.7M	294.7M	129.5M	89.5M
SG&A Expense	87.0M	63.3M	35.5M	24.3M	21.8M
General & Admin Expense	87.0M	63.3M	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	(314.7M)	—	—	—
Total Operating Expenses	499.6M	63.3M	330.1M	153.8M	111.3M
Cost and Expenses	499.6M	378.0M	334.0M	157.8M	113.4M
Operating Income (EBIT)	(463.0M)	(159.3M)	(327.0M)	(134.4M)	(62.5M)
Non-Operating
Interest Income	31.1M	45.6M	52.5M	21.5M	3.8M
Interest Expense	—	—	—	—	—
Net Interest Income	31.1M	45.6M	52.5M	21.5M	3.8M
Other Non-Op Income/Expense	43.0M	45.6M	52.5M	21.5M	3.8M
Non-Operating Income (excl Interest)	(33.2M)	—	(52.5M)	(21.5M)	(3.8M)
EBT (Pre-Tax Income)	(420.0M)	(113.7M)	(274.5M)	(113.0M)	(58.7M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(420.0M)	(113.7M)	(274.5M)	(113.0M)	(58.7M)
Earnings from Cont. Ops	(420.0M)	(113.7M)	(274.5M)	(113.0M)	(58.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(420.0M)	(113.7M)	(274.5M)	(113.0M)	(58.7M)
Per Share
Basic EPS	($4.49)	($1.28)	($3.36)	($1.96)	($1.42)
Diluted EPS	($4.49)	($1.28)	($3.36)	($1.96)	($1.42)
Revenue Per Share	$0.35	$2.47	$0.09	$0.41	$1.23
Shares
Basic Shares Outstanding	102.9M	88.5M	81.7M	57.5M	41.4M
Diluted Shares Outstanding	102.9M	88.5M	81.7M	57.5M	41.4M
Profitability Metrics
EBITDA	(427.3M)	(154.7M)	(270.6M)	(109.0M)	(56.6M)
D&A	2.5M	4.6M	3.8M	4.0M	2.1M
EBIT	(429.9M)	(159.3M)	(274.5M)	(113.0M)	(58.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026